Immunoglobulin (Ig) G4-related disease (IgG4-RD) is an entity of emerging immune-mediated diseases characterised by the infiltration of IgG4-bearing plasma cells, elevated serum IgG4 concentration, and systemic disorders present in nearly all organs with the exception of cerebral parenchyma[@b1][@b2][@b3]. The role of IgG4 in autoimmune diseases was first proposed for sclerosing or autoimmune pancreatitis (AIP) in 2001[@b4]. Since then, various organs in addition to the pancreas have been reported as involved in IgG4-related conditions[@b5]. Notably, many previously-recognised diseases, including AIP, Mikulicz's disease (MD), chronic fibrosing sialadenitis, and other sclerosing disorders, are now known to belong to the clinical spectrum of IgG4-RD[@b1].

The organ-specific diagnostic criteria for patients with IgG4-RD is likely impossible to establish due to variable organ involvements and clinical symptoms[@b6]. However, comprehensive criteria are important in clinical practice, especially in differential diagnosis from malignancies. Based on the common features of IgG4-RD, the current diagnostic criteria from Japan, Asian-Korea Consensus and Comprehensive Diagnostic Criteria generally include clinical symptoms (swelling or masses of single or multiple organs), histopathologic findings (extensive infiltration of IgG4^+^ plasma cells and fibrosis), haematological examination (concentrations of serum IgG4 \>135 mg/dl), and imaging modalities (narrowing of ducts and/or enlargement of organs)[@b6][@b7][@b8]. An elevated serum IgG4 level is one of the most helpful of these criteria. Previous studies demonstrated that serum IgG4 concentrations significantly increased in patients with IgG4-RD[@b4][@b9][@b10]. The measurement of the serum IgG4 concentration is a useful tool in disease diagnosis, evaluating disease activity and predicting the responsiveness and clinical improvement of steroid and rituximab therapy in patients with IgG4-RD[@b11][@b12].

However, many diseases other than IgG4-RD have higher levels of IgG4, and studies have suggested an unsatisfactory performance of serum IgG4 detection in the diagnosis of IgG4-RD with poor specificity and positive predictive value despite a high sensitivity and negative predictive value[@b2][@b13][@b14]. Additionally, IgG4-RD is a rare disorder with low incidence compared with other autoimmune disease, and the small sample sizes in previous studies focusing on the features of serum IgG4 level frequently led to a variable diagnostic accuracy of IgG4 in patients with IgG4-RD[@b6][@b9][@b15]. Notably, IgG4-RD is a systemic fibro-inflammatory disease that has a similar pathogenesis and cardinal features in affected organs; however, it was rarely analysed as an extensive entity but rather an individual disorder focused on a single organ, especially the pancreas and salivary or lacrimal glands[@b2][@b11][@b16][@b17][@b18][@b19].

Up to now, a comprehensive overview of the accuracy and precision of the serum IgG4 concentration for the diagnosis of all IgG4-RD has not been performed. We aimed to establish the diagnostic performance of the serum IgG4 concentration for IgG4-RD involving the pancreas, bile duct, salivary gland, and lacrimal gland from non-IgG4-RD and/or healthy controls.

Methods
=======

Search strategy
---------------

We searched the electronic databases of MEDLINE (via PubMed), EMBASE and the Web of Science from 2000 to September 2015 in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines[@b20]. The systemic search was conducted combining the terms "serum", "immunoglobulin g4" OR "igg4", as well as the terms "sclerosing pancreatitis" OR "autoimmune chronic pancreatitis" OR "autoimmune pancreatitis" OR "cholangitis" OR "sclerosing cholangitis" OR "Küttner tumor" OR "sialadenitis" OR "sclerosing sialadenitis" OR "sclerosing dacryoadenitis" OR "Mikulicz's disease" OR "igg4-rd" OR "igg4-related disease" with the species restriction of Human and language restriction of English. The relevant reference lists of the review articles were also screened to identify additional eligible articles not obtained in database searches.

Data extraction and quality assessment
--------------------------------------

Prospective or retrospective case-control studies on the utility of serum IgG4 concentration in the diagnosis of IgG4-RD were deemed eligible for inclusion in the meta-analysis. The studies also met the criteria in that serum IgG4 concentration with an unambiguous cut-off value had been evaluated between IgG4-RD with a wide variety of organs involved and other diseases, as well as healthy controls. Articles with a larger sample size or more recently published articles were included when they used the same case series. Studies for which inadequate data for confirming the diagnosis of IgG4-RD and those assessing the role of IgG4 in the pathogenic mechanism were excluded. Conference or poster abstracts without sufficient clinical information or subsequent publication in full text were excluded. Studies with fewer than 10 included patients or based on animal or cell cultures were also excluded.

Risk of bias and applicability were critically assessed according to the revised Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool, which has 4 key domains including patient selection, index text, reference standard, and flow and timing[@b21]. Risk of bias and applicability concerns were judged as "low," "high," or "unclear". Data extraction and quality assessment were performed by two reviewers (Wen-long Xu and Ying-chun Ling), and disagreements were resolved by discussion.

Statistical analysis
--------------------

The forest plot of individual and summarised sensitivity and specificity along with 95% confidence intervals (95% CIs) of the included studies were generated to graphically represent the diagnostic value of serum IgG4 in IgG4-RD. Subsequently, a hierarchical summary receiver operating characteristic (HSROC) model with a corresponding 95% confidence contour and 95% prediction contour was calculated. A bivariate random effects model following the DerSimonian-Laird method with a corresponding test of heterogeneity was used for data pooling. The heterogeneity across studies included in the meta-analysis was statistically detected using a Q test and I^2^ statistics, which ranged from 0 to 100% and were interpreted as representing low, medium and high inconsistency with the values of ≤25%, ≤50% and ≤75%, respectively, in accordance with the proposal of Higgins and Thompson[@b22]. Stratified analysis and meta-regression based on variations in features of ethnicity, spectrum of IgG4-RD and detection method were performed to explore potential sources of heterogeneity. Publication biases were tested using Egger precision weighted linear regression tests and sensitivity analysis and demonstrated graphically using funnel plots. The causes of heterogeneity were further assessed using a sensitivity analysis in which the sequential omission of individual studies was performed to analyse the influence of a single study on the overall detection rate of IgG4-RD. The meta-analysis of the data was conducted using the Stata/SE version 13.1 (StataCorp LP, Texas, USA). P \< 0.05 was considered statistically significant.

Results
=======

Study identification and selection
----------------------------------

The initial keyword search yielded 2071 potentially relevant studies from the databases of PubMed (n = 533), Embase (n = 708), and the Web of Science (n = 830). After 464 duplicates were discarded, 1607 articles remained, of which the title and abstract were screened for eligibility in the meta-analysis. In accordance with the predefined inclusion criteria, 1472 articles were removed, and the remaining 135 articles were deemed potentially relevant. Following the further review of the full text articles, 111 studies were excluded due to improper design for data extraction (n = 70), insufficient data for fourfold table construction (n = 38), duplicated publication (n = 2) and published in a language other than English (n = 1). Finally, 23 articles were considered as eligible and included in this meta-analysis ([Fig. 1](#f1){ref-type="fig"}). No disagreement occurred between the two reviewers.

Study characteristics and methodological quality
------------------------------------------------

In total, 6048 patients in 23 studies were included in the spectrum of IgG4-RD including AIP (13 studies), MD (3 studies), IgG4-associated cholangitis (6 studies) and IgG4-RD without further classification according to the organ involved (4 studies). The study type included 10 retrospective studies, 6 prospective studies and 7 studies without reporting the study type. Ethnicity included Asian in 15 studies with 3931 patients and Caucasian in 8 studies with 2117 patients ([Table 1](#t1){ref-type="table"}).

Overall, the included studies were of moderate methodological quality according to the QUADAS-2 tool. The high risk of bias and concerns of applicability regarding patient selection were introduced because all included studies were of a randomised or case-control design. The risk of bias for the index test and reference standard remained either (1) unclear because the index test and/or reference standard were interpreted double-blindly in all included studies with the exception of one[@b23] or (2) high because the index test of serum IgG4 was not reported in five studies[@b24][@b25][@b26][@b27][@b28]. There were no major concerns regarding the applicability of the reference standard for the included studies. The risk of bias on flow and timing arose from the fact that the description of the interval and interventions between index tests and the reference standard were not reported in all studies ([Table 1](#t1){ref-type="table"}).

Overall diagnostic accuracy
---------------------------

Serum IgG4 with a cut-off value ranging from 130 mg/dL to 200 mg/dL was detected using the assay methods of nephelometry (15 studies), single radial immunodiffusion (2 studies) and ELISA (1 study). Notably, the assay of serum IgG4 was not reported in 5 studies. The sensitivity and specificity of serum IgG4 concentration for the diagnosis of IgG4-RD ranged from 32% to 100% and from 59% to 100%, respectively ([Table 2](#t2){ref-type="table"}). The pooled sensitivity and specificity were 85% with a 95% confidence interval (CI) of 78--90% and 93% with a 95% CI of 90--95%, respectively ([Fig. 2](#f2){ref-type="fig"}). The Q tests for pooled sensitivity and specificity were 181.74 with I^2^ of 87.89 (95% CI 83.89%, 91.90%) (p \< 0.01) and 482.65 with I^2^ of 95.44 (95% CI 94.32%, 96.57%) (p \< 0.01), both of which suggested significant heterogeneity ([Fig. 3](#f3){ref-type="fig"}). The diagnostic odds ratio and positive and negative likelihood ratios were 70 (95% CI 42, 116), 11.6 (95% CI 8.1, 16.5) and 0.17 (95% CI 0.11, 0.24), respectively. These results strongly indicated that the higher rate of serum IgG4 positivity increased the chance of diagnosing IgG4-RD.

The diagnostic values of the studies were demonstrated in a HSROC graph in which the summary operating point represents the pooled sensitivity and specificity, as well as 95% confidence and the prediction region represents 95% CI of the pooled and individual sensitivity and specificity. The HSROC curve for quantitative serum IgG4 lies closer to the upper left corner of the HSROC plot, and the area under the curve (AUC) was 0.95 (95% CI 0.93, 0.97), which suggested an impressive diagnostic accuracy of serum IgG4 for the entity of IgG4-RD. Finally, the curve is symmetrical with the Z statistic of −0.58 (p = 0.564), which also indicates a high diagnostic accuracy for serum IgG4 ([Fig. 4](#f4){ref-type="fig"}).

Subgroup analysis and publication bias
--------------------------------------

The subgroup analysis was performed according to study period (published before vs. after 2011), study design (designed prospectively vs. retrospectively), sample size (less than 150 vs. more than 150), ethnicity (Asian vs. Caucasian), and serum IgG4 concentration detection assay (nephelometry vs. another method). The sensitivity of serum IgG4 was higher for (1) the studies published after 2011, (2) retrospective studies performed before 2011 that used detection methods other than assays, and (3) prospective studies using the method of nephelometry, whereas specificity was significantly different between the subgroups of all variables for the diagnosis of IgG4-RD ([Table 3](#t3){ref-type="table"}).

Egger's regression test did not reveal any publication bias arising from small-study effects (p  =  0.30) ([Fig. 4](#f4){ref-type="fig"}). A sensitivity analysis suggested only a minor influence for diagnostic accuracy of omitting single-study estimates from 3 studies with larger sample sizes[@b2][@b29][@b30]; however, the estimates still fall within the indicated spread of lower and higher CI limits ([Fig. 5](#f5){ref-type="fig"}).

Discussion
==========

Accurately differentiating IgG4-RD from malignancies such as pancreatic cancer is very important to avoid unnecessary surgeries. Compared with the histopathological criteria, the detection of serum IgG4 is one of the most convenient and valuable non-invasive examinations in clinical practice for the diagnosis of IgG4-RD, especially in disease screening at an early stage. However, because the positive rate of serum IgG4 varied according to different studies, the diagnostic accuracy of this method is controversial. A previous meta-analysis published in 2009 demonstrated that the serum IgG4 is a good marker of a single disease of AIP with a pooled sensitivity ranging from 82.3% to 89.3% and a specificity of 94.6% to 95.8% according to different control[@b31]. Beyond that, no studies were carried out to systematically summarise the currently available data on the performance of serum IgG4 for the diagnosis of IgG4-RD as an entity.

In the last decade, numerous studies have attempted to evaluate the diagnostic value of serum IgG4 in IgG4-RD. To summarise these studies, we conducted this meta-analysis, which included 23 studies comprising a total of 6048 patients with IgG4-RD diagnosed with different criteria. The key findings of our analysis are that serum IgG4 has a very high accuracy for sensitivity (85%) and specificity (93%) in detecting IgG4-RD involving the pancreas, bile duct, salivary gland, or lacrimal gland from non-IgG4-RD involving the same organs and/or healthy controls (or both). The serum IgG4 has a higher summarised sensitivity and specificity compared with the histopathological method using the infiltration of IgG4-positive plasma cells in which the pooled sensitivity and specificity were 58.8% and 90.2%, respectively[@b32]. The diagnostic value of serum IgG4 remained significant with a sensitivity range from 78% to 88% and a specificity range from 90% to 95% when analysed separately in different subgroups. An association between the sensitivity or specificity and the study period, study, sample size, ethnicity, or detection assay of serum IgG4 were also identified using meta-regression and subgroup analysis. The findings of such an assessment are useful both in providing evidence-based patient information in clinical application and further investigation.

Our meta-analysis had several limitations. Firstly, there was inevitable heterogeneity in the meta-analysis of diagnostic accuracy due to the variability in design characteristics and the poor quality of reporting in the primary studies. The quality of the studies included in the meta-analysis was modest for our meta-analysis because ten studies were retrospective designed[@b19][@b23][@b24][@b25][@b26][@b27][@b28][@b29][@b33][@b34], six studies were prospective designed[@b11][@b16][@b18][@b30][@b35][@b36], and seven studies did not report the study design[@b2][@b9][@b10][@b15][@b17][@b37][@b38]. The QUADAS-2 tools for the methodological assessment indicated that other contributors to the potential heterogeneity across the studies result from the risk bias in patient selection due to the diagnosis of IgG4-RD on the basis of multiple criteria, as well as due to the detection method for serum IgG4 despite the clear cut-off value given in several studies[@b24][@b25][@b26][@b27][@b28]. Regarding procedure and timing, the interval and whether there were any interventions between the index tests and the reference standard were not described in all studies. Secondly, because differing cutoff values were used in the same primary studies[@b2][@b11][@b18][@b35], widely accepted values varying from 135 mg/dL (range 130 mg/dL to 200 mg/dL) were employed in the meta-analysis. It was not possible to assess a threshold effect for an optimum serum IgG4 concentration. Finally, several studies with high quality were excluded because the results were reported in the form of means and SD, which may contribute to the heterogeneity and may have impaired the stringency of the meta-analysis.

Serum IgG4 is a more cost-effective, easy and a time-efficient assay that can be carried out to detect IgG4-RD. We conclude that this meta-analysis has achieved its primary objectives by demonstrating that the detection of serum IgG4 has high sensitivity and represents a specific investigative modality in the detection of IgG4-RD as an indicator. However, this does not necessarily indicate that the positive or negative serum IgG4 could be used to rule out (or confirm) a diagnosis of IgG4-RD. A diagnosis based on IgG4-RD should be made after comprehensive analysis that considers clinical symptoms, as well as histopathologic, haematological, and imaging findings. The histopathological assessment of biopsy specimens from the involved tissues remains the cornerstone in both the definite diagnosis of IgG4-RD and the exclusion of malignancies. In summary, appropriate considerations and cautious interpretations of these findings combined with other parameters (especially pathological examination) are highly recommended, and additional studies that evaluate the accuracy of IgG4 in a wider spectrum of IgG-RD are needed.
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The corresponding heterogeneity of Q test with p \< 0.01 and I^2^  \> 75% suggests significant heterogeneity.](srep32035-f2){#f2}
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![Meta-analysis estimates, given named study is omitted.\
The results shows that only little variation in summarized detection rate estimates of IgG4-RD is induced by omission of the one selected study. No systematic bias is identified although strong heterogeneity amongst studies is indicated. (Mantel-Haenzel fix model, statistic of relative risk).](srep32035-f5){#f5}

###### Characteristics of included studies.

  Author                       Year   Study location   Ethnicity   Study design                                   Criteria for IgG4-RD                                    IgG4-RD disease (No.)                                           Control (No.)                                          Risk of bias\*   Applicability concerns\*
  --------------------------- ------ ---------------- ----------- --------------- ------------------------------------------------------------------------------------- ------------------------- --------------------------------------------------------------------------------------------- ---------------- --------------------------
  Aparisi *et al*.             2005       Spain        Caucasian        NR                       Histopathological, clinical, and laboratory parameters                         AIP (25)                                                    ICP (29)                                                  P^†^                   No
  Boonstra *et al*.            2014       Dutch        Caucasian    Prospective                               Mayo Clinic's HISORt criteria                                     IAC (73)                                                  PSC (n = 310)                                                P                     No
  Carruthers *et al*.          2015        USA         Caucasian        NR                         International pathology consensus guideline (2012)                         IgG4-RD (72)                                    AID (n = 11), other disease (n = 397)                                    P                     No
  Choi *et al*.                2007       Korea          Asian          NR                                    Asan Medical Center of Korea                                      AIP (30)                                            PC (n = 76); CP (n = 67)                                           P                     No
  Ghazale *et al*.             2007        USA         Caucasian    Prospective                               Mayo Clinic's HISORt criteria                                     AIP (45)                    PC (n = 135), other pancreatic diseases (n = 268); other disease (n = 62)                  P                     No
  Hamano *et al*.              2001       Japan          Asian     Retrospective                 Ultrasonographic, clinical, and laboratory performance                         AIP (20)                  PC (n = 70), CP (n = 45), PBC (n = 20), PSC (n = 8), SS (n = 11), HC (n = 20)                P                     No
  Hirano *et al*.              2006       Japan          Asian     Retrospective                                 Japan Pancreas Society                                         AIP (35)                     CP (n = 24), PSC (n = 11), PC (n = 23), biliopancreatic cancer (n = 23)                   P                     No
  Kaji *et al*.                2012       Japan          Asian      Prospective                        AIP: Asian criteria (Japan--Korea) and ICDC                              AIP (35)                         PC (n = 17), CP (n = 24), PSC (n = 7), biliary cancer (n = 23)                        P                     No
  Kamisawa *et al*.            2008       Japan          Asian     Retrospective                   Radiological, serological histological examination                           AIP (17)                                                   PC (n = 33)                                              P, I^\#^                 I
  Masaki *et al*.              2012       Japan          Asian     Retrospective                        Pathological and clinical manifestations                              IgG4-RD (132)                                    SS (n = 33), other non-AID (n = 15)                                    P, I                   I
  Mavragani *et al*.           2014       Greece       Caucasian   Retrospective                                 Comprehensive criteria                                        IgG4-RD (7)                                               SS (n = 126)\*                                                P                     No
  Nakazawa *et al*.            2012       Japan          Asian     Retrospective                  IgG4-SC: Japanese criteria 2006; AIP: HISORt criteria                         IAC (47)                                     PC (n = 26), PSC (n = 21), CCA (n = 18)                                  P, I                   I
  Ohara *et al*.               2013       Japan          Asian     Retrospective                             ICDC, revised Japanese criteria                                    IAC (344)                                  PC (n = 245), PSC (n = 110), CCA (n = 149)                                  P                     No
  Oseini *et al*.              2011        USA         Caucasian    Prospective                               Mayo Clinic's HISORt criteria                                     IAC (97)                                                  CCA (n = 287)                                                P                     No
  Sanchez-Castanon *et al*.    2012       Spain        Caucasian   Retrospective                              Mayo Clinic's HISORt criteria                                     AIP (12)           CP (n = 23), ICP (n = 26), AP (n = 11), PC (n = 21), SS (n = 9), T1DM (n = 40), HC (n = 45)         P                     No
  Su *et al*.                  2015       China          Asian          NR                                           Japan criteria                                           IgG4-RD (12)                                   AID (n = 127), other disease (n = 818)                                    P                     No
  Szántó *et al*.              2014       Japan          Asian          NR                                 Japanese Research Committee (2011)                                  AIP, MD (8)                                                 SS (n = 43)                                                 P                     No
  Tabata *et al*.              2011       Japan          Asian      Prospective    AIP: Asian criteria (Japan--Korea); MD: Clinical performance and exclusive criteria        AIP, MD (66)                         Other pancreatobiliary or salivary gland diseases (n = 488)                         P                     No
  Tanaka *et al*.              2015       Japan          Asian     Retrospective                           Japanese Biliary Association (2012)                                  IAC (38)                                                  PSC (n = 120)                                               P, I                   I
  Uehara *et al*.              2005       Japan          Asian          NR                       Histopathological, clinical, and laboratory parameters                        AIP-SC (6)                                                    PSC (6)                                                   P                     P
  Van Heerde *et al*.          2014       Dutch        Caucasian    Prospective                 ICDC, Asian or HISORT criteria, or comprehensive criteria                       AIP (33)                                                   PC (n = 53)                                                 P                     P
  Wu *et al*.                  2013       China          Asian     Retrospective                       Pathological and radiologic manifestations                               AIP (15)                                                 Non-AIP (n = 4)                                              P, I                   No
  Yamamoto *et al*.            2012       Japan          Asian          NR                            Mayo Clinic's HISORt criteria; Japan criteria                      AIP, MD, CFSA, DA (102)                       AID (n = 206), other disease (n = 72), HC (n = 21)                              P                     P

IgG4-RD: IgG4-related disease; AIP: autoimmune chronic pancreatitis; MD: Mikulicz's disease; IAC: IgG4-associated cholangitis; CFSA: Chronic fibrosing sialoadenitis; DA: IgG4-related dacryoadenitis; PC: pancreatic cancer; CP: chronic pancreatitis other than AIP; ICP: idiopathic chronic pancreatitis; PBC: primary biliary cirrhosis; SS: Sjögren's syndrome; CCA: cholangiocarcinoma; HC: healthy control; T1DM: type 1 diabetes mellitus; AID: autoimmune diseases; ICDC: International consensus diagnostic criteria; NR: not reported. \*QUADAS score; ^†^P: patient selection; ^\#^I: index test.

###### Diagnostic accuracy of serum IgG4 concentration for individual study.

  Author                       Year   Assay for IgG4   Cut-off (mg/dL)   Participant, n   True positive   False positive   False negative   True negative   Sensitivity   Specificity
  --------------------------- ------ ---------------- ----------------- ---------------- --------------- ---------------- ---------------- --------------- ------------- -------------
  Aparisi *et al*.             2005    Nephelometry          130               54               8               0                17              29             32%          100%
  Boonstra *et al*.            2014    Nephelometry          140              383              66               45               7               265            90%           85%
  Carruthers *et al*.          2015    Nephelometry          135              380              65              125               7               183            90%           59%
  Choi *et al*.                2007        SRI               135              173              22               9                8               134            73%           94%
  Ghazale *et al*.             2007    Nephelometry          140              510              34               32               11              433            76%           93%
  Hamano *et al*.              2001        SRI               135              194              19               3                1               171            95%           98%
  Hirano *et al*.              2006    Nephelometry          135              116              33               4                2               77             94%           95%
  Kaji *et al*.                2012    Nephelometry          135              106              32               2                3               69             91%           97%
  Kamisawa *et al*.            2008         NR               135               50              12               2                5               31             71%           94%
  Masaki *et al*.              2012         NR               135              180              128              10               4               38             97%           79%
  Mavragani *et al*.           2014    Nephelometry          135              133               3               7                4               119            43%           94%
  Nakazawa *et al*.            2012         NR               135              112              41               6                6               59             87%           91%
  Ohara *et al*.               2013    Nephelometry          135              848              309              41               35              463            90%           92%
  Oseini *et al*.              2011    Nephelometry          140              384              69               37               28              250            71%           87%
  Sanchez-Castanon *et al*.    2012    Nephelometry          130              187               7               10               5               165            58%           94%
  Su *et al*.                  2015       ELISA              135              957              12               32               0               913           100%           97%
  Szántó *et al*.              2014    Nephelometry          135               51               7               1                1               42             88%           98%
  Tabata *et al*.              2011    Nephelometry          135              554              53               31               13              457            80%           94%
  Tanaka *et al*.              2015         NR               135              158              34               15               4               105            89%           88%
  Uehara *et al*.              2005    Nephelometry          135               12               6               0                0                6            100%          100%
  Van Heerde *et al*.          2014    Nephelometry          140               86              28               10               5               43             85%           81%
  Wu *et al*.                  2013         NR               200               19               8               0                7                4             53%          100%
  Yamamoto *et al*.            2012    Nephelometry          144              401              97               28               5               271            95%           91%

**SRI:** single radial immunodiffusion; **NR:** not reported.

###### Subgroup analysis of the sensitivity and specificity of serum IgG4 for the diagnostic performance of IgG4-RD.

  Parameter          Category      No. of study     Sensitivity     p      Specificity     p
  --------------- --------------- --------------- --------------- ------ --------------- ------
  Period            Before 2011          9         78% (67--90%)   0.00   95% (92--98%)   0.00
  After 2011            14         88% (82--94%)   91% (87--95%)                         
  Study design      Prospective          6         83% (74--93%)   0.04   90% (86--94%)   0.00
  Retrospective         10         85% (77--92%)   93% (91--96%)                         
  Sample size      Less than 150        13         88% (82--94%)   0.35   91% (87--95%)   0.00
  More than 150         10         79% (67--90%)   95% (92--98%)                         
  Ethnicity            Asian            15         88% (83--93%)   0.63   94% (92--97%)   0.00
  Caucasian              8         73% (61--86%)   90% (84--95%)                         
  Assay            Nephelometry         15         83% (75--91%)   0.02   92% (89--95%)   0.00
  Other method           8         87% (78--96%)   94% (90--98%)                         

[^1]: These authors contributed equally to this work.
